Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
5.4.22
FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
4.28.22
Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis
3.29.22
NovaQuest Capital Management Acquires TechAccel’s Interest In Covenant Animal Health Partners
11.30.21
Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals
9.20.21
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
8.24.21
Dermavant Announces $200 Million of Financing
6.7.21
Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
6.1.21
Argenta Enters $30 Million Product Financing Agreement with NovaQuest to Accelerate New Veterinary Product Development
5.20.21
Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
5.3.21